<p>DAWNRAYS PHARMA (02348.HK) announced its interim results for the six months ending in June, with revenue of RMB 630 million, a year-on-year decrease of 9.2%. It recorded a net profit of RMB 105 million, a decline of 78.8%, with earnings per share of 6.961 cents. The interim dividend remains at 1.5 Hong Kong cents</p>

02348

<p>DAWNRAYS PHARMA announced its interim results for the six months ended June, with revenue of RMB 630 million, a year-on-year decrease of 9.2%. It recorded a net profit of RMB 105 million, a decline of 78.8%, with earnings per share of 6.961 cents. The interim dividend remains at 1.5 HK cents</p>

"Performance" DAWNRAYS PHARMA's mid-term net profit is 105 million RMB, down 78.8%, with a dividend of 1.5 HK cents